Contineum Therapeutics, Inc. Class A (CTNM)

Contineum Therapeutics' stock has been impacted by several events in the past six months. On November 20, 2025, the stock fell 26% after PIPE-307 failed to meet efficacy endpoints in a Phase 2 trial. On December 11, 2025, the company announced a proposed $75.0 million public offering, which was later upsized to $90.0 million. On January 8, 2026, Morgan Stanley downgraded the stock from "Overweight" to "Equalweight," lowering the price target due to mechanistic uncertainty and extended development timelines. The company adopted a 2026 Employment Inducement Equity Plan on January 26, 2026, and reported an inducement grant on January 28, 2026. On January 30, 2026, the General Counsel received a grant of stock options. On February 2, 2026, the stock reached a new 52-week high of $15.00.

Information regarding demand seasonality for Contineum Therapeutics, Inc.'s products and services is not available. As a clinical-stage biopharmaceutical company, its primary focus is on drug development, and its product candidates are not yet commercially available.

Contineum Therapeutics, Inc. (CTNM) is a clinical-stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology (NI&I) indications. The company is advancing a pipeline of internally-developed programs with multiple drug candidates in clinical trials, including PIPE-791, a LPA1R inhibitor for IPF, PrMS, and chronic pain; PIPE-307, a M1 receptor inhibitor for RRMS and major depressive disorder; and CTX-343, a peripherally restricted LPA1R antagonist.

Contineum Therapeutics, Inc. is headquartered in San Diego, California, United States. Information regarding its broader geographic operational footprint is not explicitly available.

Contineum Therapeutics' reputation is closely tied to the progress of its clinical trials. The failure of the PIPE-307 Phase 2 clinical trial likely had a negative impact, as evidenced by the stock price drop and analyst downgrade. The Morgan Stanley downgrade, citing mechanistic uncertainty and delayed development timelines for PIPE-791, also suggests a cautious view from the financial community.

Contineum Therapeutics, Inc. has 76 institutional owners and shareholders holding a total of 18,340,337 shares. Major institutional owners include RA Capital Management, L.P., Johnson & Johnson Innovation - JJDC, Inc., Suvretta Capital Management, LLC, Franklin Resources Inc, Vanguard Group Inc, Balyasny Asset Management Llc, Fmr Llc, Sectoral Asset Management Inc, Perceptive Advisors Llc, Hillhouse Capital Advisors, Ltd., Baker Bros. Advisors LP, Averill Master Fund, Ltd., and Perceptive Life Sciences Master Fund, Ltd.